Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 May 2018
At a glance
- Drugs SGN CD352A (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2017 According to a Seattle Genetics media release, the first patient has been enrolled in this trial.
- 01 Dec 2016 Status changed from not yet recruiting to recruiting.